BridgeBio Oncology Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule oncology programs for RAS and PI3Kα malignancies. Its 8-K reports cover material events such as leadership and board changes, compensatory arrangements, clinical-data press releases, and operating or financial results.
Proxy materials describe annual meeting matters, director elections, board classification, auditor ratification, and governance practices. The company’s filings also identify its common stock capital structure and formal disclosure categories for clinical and regulatory updates, governance, compensation, and public-company reporting obligations.
BridgeBio Oncology Therapeutics, Inc. is registering 63,054,549 shares of Common Stock for resale by selling securityholders under Prospectus Supplement No. 8 dated June 22, 2026.
The supplement attaches a Form 8-K reporting governance items from the June 16, 2026 annual meeting, including director election results, ratification of Deloitte & Touche LLP, and that 80,112,725 shares were entitled to vote at the meeting with 48,344,441 shares present or represented by valid proxy. The supplement updates and supplements the Prospectus dated September 10, 2025.
BridgeBio Oncology Therapeutics, Inc. reported results from its June 16, 2026 Annual Meeting of Stockholders and a board change. Director Michelle Doig resigned from the Board at the end of her term as a Class I director, and the company stated her resignation was not due to any disagreement regarding operations, policies or practices.
Stockholders elected two Class I directors. Peter Lebowitz received 31,822,504 votes for and 3,372 withheld. Frank P. McCormick received 25,654,119 votes for and 6,171,757 withheld. The company reported 2,713,439 broker non-votes and 13,805,126 no votes on this proposal.
Stockholders also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 34,535,875 votes for, 3,440 against and no abstentions, and 13,805,126 no votes reported for this proposal.
BridgeBio Oncology Therapeutics director Praveen P. Tipirneni received a stock option grant for 31,675 shares of Common Stock. The option has an exercise price of $7.73 per share and expires on June 15, 2036. It vests in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders, subject to his continued service. Following this grant, he holds options for 31,675 shares directly, with no open-market buying or selling reported in this filing.
BridgeBio Oncology Therapeutics director Frank McCormick received a new stock option grant. He was awarded options for 31,675 shares of common stock at an exercise price of $7.73 per share. These options were granted at no upfront cost and are held as a direct ownership position.
The options vest in full on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, as long as he continues serving the company through that date. Following this grant, his reported derivative holdings from this award total 31,675 underlying shares.
BridgeBio Oncology Therapeutics director Peter F. Lebowitz received a grant of stock options covering 7,289 shares of common stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036. According to the terms, they vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders, provided he continues serving the company through that vesting date. After this grant, Lebowitz holds 7,289 stock options directly.
BridgeBio Oncology Therapeutics director Raymond J. Kelleher received a new stock option grant covering 31,675 shares of Common Stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036, giving him the right to buy shares at that price in the future.
The award vests in full on the earlier of the first anniversary of the June 16, 2026 grant date or the next Annual Meeting of Stockholders, as long as he continues serving the company through that date. After this grant, he holds 31,675 stock options directly.
BridgeBio Oncology Therapeutics director and 10% owner Chen Bihua received a grant of stock options for 31,675 shares of common stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036.
The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders that follows the grant date, provided Chen continues to serve the company through that vesting date. After this grant, Chen holds 31,675 derivative securities directly.
BridgeBio Oncology Therapeutics, Inc. director Jake Bauer reported a compensation-related stock option grant covering 31,675 shares of common stock at an exercise price of $7.73 per share. The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders, and expire on June 15, 2036. Following this grant, Bauer holds stock options for 31,675 underlying shares directly.
BridgeBio Oncology Therapeutics director Neil Kumar received a stock option grant for 31,675 shares of common stock at an exercise price of $7.73 per share. The option vests in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued service, and expires in 2036. Following this grant, he holds 31,675 derivative securities directly.
Registration of 63,054,549 shares of Common Stock by the Selling Securityholders. This Prospectus Supplement No. 7 to the Prospectus (Registration No. 333-289940) registers 63,054,549 shares of common stock for resale by selling holders and attaches the Company’s Form 10-Q for the quarterly period ended March 31, 2026.
The supplement updates the Prospectus and should be read with it. The attached Form 10-Q reports a net loss of $42.1 million for the three months ended March 31, 2026 and cash, cash equivalents, and marketable securities of approximately $388.9 million as of March 31, 2026. Shares outstanding were 80,107,104 as of May 7, 2026.